6 August 2020AmericasMuireann Bolger

Federal Circuit won’t revisit revived Illumina DNA test patents

The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Appeals court eases Teva’s headache with reversal

17 April 2026 A ruling that invalidated three of Teva's headache treatment patents has been thrown out, sending a long-running case back to the lower court.

Americas

Cancer drug researcher hit with suit over mutation-targeting tools

16 April 2026 The Cambridge biotech is accused of infringing six patents covering technologies used to target drug-resistant cancer mutations.

Americas

Court narrows Mylan’s Copaxone suit but key claims survive

14 April 2026 A US district court has allowed key elements of the generic drugmaker’s case against a rival to move forward, while drawing clear limits on how far the complaint can reach.

More features

Appeals court eases Teva’s headache with reversal

Simmons & Simmons makes senior Asia trademark hire

Baker McKenzie strengthens IP bench with new German lead

Cancer drug researcher hit with suit over mutation-targeting tools

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

Court narrows Mylan’s Copaxone suit but key claims survive

IP finance gap risks startup exodus, EUIPO warns

Oracle retaliates with lawsuit to laid-off staff member’s ‘demands’

Federal Circuit won’t revisit revived Illumina DNA test patents

More on this story

Editor's picks

Editor's picks

More features